Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Finding the relevance of antimicrobial stewardship for cystic fibrosis.

Cogen JD, Kahl BC, Maples H, McColley SA, Roberts JA, Winthrop KL, Morris AM, Holmes A, Flume PA, VanDevanter DR, Waters V, Muhlebach MS, Elborn JS, Saiman L, Bell SC; Antimicrobial Resistance International Working Group in Cystic Fibrosis.

J Cyst Fibros. 2020 Feb 29. pii: S1569-1993(20)30059-X. doi: 10.1016/j.jcf.2020.02.012. [Epub ahead of print] Review.

PMID:
32122785
2.

The demographics of adverse outcomes in cystic fibrosis.

McGarry ME, Williams WA 2nd, McColley SA.

Pediatr Pulmonol. 2019 Nov;54 Suppl 3:S74-S83. doi: 10.1002/ppul.24434. Review.

PMID:
31715087
3.

Cystic fibrosis year in review 2018, part 2.

Savant AP, McColley SA.

Pediatr Pulmonol. 2019 Aug;54(8):1129-1140. doi: 10.1002/ppul.24365. Epub 2019 May 24. Review.

PMID:
31125191
4.

Cystic fibrosis year in review 2018, part 1.

Savant AP, McColley SA.

Pediatr Pulmonol. 2019 Aug;54(8):1117-1128. doi: 10.1002/ppul.24361. Epub 2019 May 20. Review.

PMID:
31106528
5.

Inconclusive diagnosis after a positive newborn bloodspot screening result for cystic fibrosis; clarification of the harmonised international definition.

Southern KW, Barben J, Gartner S, Munck A, Castellani C, Mayell SJ, Davies JC, Winters V, Murphy J, Salinas D, McColley SA, Ren CL, Farrell PM.

J Cyst Fibros. 2019 Nov;18(6):778-780. doi: 10.1016/j.jcf.2019.04.010. Epub 2019 Apr 24. No abstract available.

PMID:
31027826
6.

Transition to adulthood and adult health care for patients with sickle cell disease or cystic fibrosis: Current practices and research priorities.

Lanzkron S, Sawicki GS, Hassell KL, Konstan MW, Liem RI, McColley SA.

J Clin Transl Sci. 2018 Oct;2(5):334-342. doi: 10.1017/cts.2018.338. Review.

7.

Cystic fibrosis and portal hypertension: Distal splenorenal shunt can prevent the need for future liver transplant.

Lemoine C, Lokar J, McColley SA, Alonso EM, Superina R.

J Pediatr Surg. 2019 May;54(5):1076-1082. doi: 10.1016/j.jpedsurg.2019.01.035. Epub 2019 Feb 2.

PMID:
30792095
8.

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study.

McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS.

Lancet Respir Med. 2019 Apr;7(4):325-335. doi: 10.1016/S2213-2600(18)30460-0. Epub 2019 Jan 24.

PMID:
30686767
9.

Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

McColley SA, Konstan MW, Ramsey BW, Stuart Elborn J, Boyle MP, Wainwright CE, Waltz D, Vera-Llonch M, Marigowda G, Jiang JG, Rubin JL.

J Cyst Fibros. 2019 Jan;18(1):94-101. doi: 10.1016/j.jcf.2018.07.011. Epub 2018 Aug 23.

10.

Cystic fibrosis year in review 2017.

Savant AP, McColley SA.

Pediatr Pulmonol. 2018 Sep;53(9):1307-1317. doi: 10.1002/ppul.24081. Epub 2018 Jun 21. Review.

PMID:
29927544
11.

Designing trials for new cystic fibrosis modulators.

Cunningham S, McColley SA.

Lancet Respir Med. 2018 Jul;6(7):484-486. doi: 10.1016/S2213-2600(18)30195-4. Epub 2018 May 31. Review. No abstract available.

PMID:
29859920
12.

Are children with chronic illnesses requiring dietary therapy at risk for disordered eating or eating disorders? A systematic review.

Conviser JH, Fisher SD, McColley SA.

Int J Eat Disord. 2018 Mar;51(3):187-213. doi: 10.1002/eat.22831. Epub 2018 Feb 22. Review.

PMID:
29469935
13.

The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype.

Espel JC, Palac HL, Bharat A, Cullina J, Prickett M, Sala M, McColley SA, Jain M.

J Cyst Fibros. 2018 Jan;17(1):34-42. doi: 10.1016/j.jcf.2017.11.002. Epub 2017 Dec 6.

PMID:
29221674
14.

Antibiotic duration and changes in FEV1 are not associated with time until next exacerbation in adult cystic fibrosis: a single center study.

Espel JC, Palac HL, Cullina JF, Clarke AP, McColley SA, Prickett MH, Jain M.

BMC Pulm Med. 2017 Nov 29;17(1):160. doi: 10.1186/s12890-017-0503-6.

15.

Airway microbiota across age and disease spectrum in cystic fibrosis.

Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP, Gibson RL, Harris WT, Kurland G, Laguna TA, McColley SA, McCoy K, Retsch-Bogart G, Sobush KT, Zeitlin PL, Stevens MJ, Accurso FJ, Sagel SD, Harris JK.

Eur Respir J. 2017 Nov 16;50(5). pii: 1700832. doi: 10.1183/13993003.00832-2017. Print 2017 Nov.

16.

The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.

Talamo Guevara M, McColley SA.

Expert Opin Drug Saf. 2017 Nov;16(11):1305-1311. doi: 10.1080/14740338.2017.1372419. Epub 2017 Sep 21. Review.

17.

Cystic fibrosis year in review 2016.

Savant AP, McColley SA.

Pediatr Pulmonol. 2017 Aug;52(8):1092-1102. doi: 10.1002/ppul.23747. Epub 2017 Jun 13. Review.

PMID:
28608632
18.

Risk factors for mortality before age 18 years in cystic fibrosis.

McColley SA, Schechter MS, Morgan WJ, Pasta DJ, Craib ML, Konstan MW.

Pediatr Pulmonol. 2017 Jul;52(7):909-915. doi: 10.1002/ppul.23715. Epub 2017 Apr 24.

PMID:
28436621
19.

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.

Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M, Sermet-Gaudelus I, Southern KW, Marshall BC, Sosnay PR.

J Pediatr. 2017 Feb;181S:S4-S15.e1. doi: 10.1016/j.jpeds.2016.09.064. Erratum in: J Pediatr. 2017 May;184:243.

20.

Diagnosis of Cystic Fibrosis in Screened Populations.

Farrell PM, White TB, Howenstine MS, Munck A, Parad RB, Rosenfeld M, Sommerburg O, Accurso FJ, Davies JC, Rock MJ, Sanders DB, Wilschanski M, Sermet-Gaudelus I, Blau H, Gartner S, McColley SA.

J Pediatr. 2017 Feb;181S:S33-S44.e2. doi: 10.1016/j.jpeds.2016.09.065.

21.

Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.

Rowe SM, McColley SA, Rietschel E, Li X, Bell SC, Konstan MW, Marigowda G, Waltz D, Boyle MP; VX09-809-102 Study Group.

Ann Am Thorac Soc. 2017 Feb;14(2):213-219. doi: 10.1513/AnnalsATS.201609-689OC.

22.
23.

Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene.

Prickett MH, Hauser AR, McColley SA, Cullina J, Potter E, Powers C, Jain M.

Thorax. 2017 Jan;72(1):40-47. doi: 10.1136/thoraxjnl-2015-208027. Epub 2016 Jun 20.

24.

Pediatric Pulmonology year in review 2015: Part 4.

Savant AP, McColley SA.

Pediatr Pulmonol. 2016 Jul;51(7):754-65. doi: 10.1002/ppul.23470. Epub 2016 May 12. Review.

PMID:
27171478
25.

A safety evaluation of ivacaftor for the treatment of cystic fibrosis.

McColley SA.

Expert Opin Drug Saf. 2016 May;15(5):709-15. doi: 10.1517/14740338.2016.1165666. Epub 2016 Apr 7. Review.

PMID:
26968005
26.

Refining the continuum of CFTR-associated disorders in the era of newborn screening.

Levy H, Nugent M, Schneck K, Stachiw-Hietpas D, Laxova A, Lakser O, Rock M, Dahmer MK, Biller J, Nasr SZ, Baker M, McColley SA, Simpson P, Farrell PM.

Clin Genet. 2016 May;89(5):539-49. doi: 10.1111/cge.12711. Epub 2016 Jan 20.

27.

Sorting out the gray zone: Cystic fibrosis newborn screening.

McColley SA.

J Cyst Fibros. 2015 Nov;14(6):681-2. doi: 10.1016/j.jcf.2015.10.003. Epub 2015 Oct 21. No abstract available.

28.

2014 year in review: Cystic fibrosis.

Savant AP, McColley SA.

Pediatr Pulmonol. 2015 Nov;50(11):1147-56. doi: 10.1002/ppul.23309. Epub 2015 Sep 7. Review.

PMID:
26347000
29.

Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.

Moss RB, Flume PA, Elborn JS, Cooke J, Rowe SM, McColley SA, Rubenstein RC, Higgins M; VX11-770-110 (KONDUCT) Study Group.

Lancet Respir Med. 2015 Jul;3(7):524-33. doi: 10.1016/S2213-2600(15)00201-5. Epub 2015 Jun 9.

30.

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group.

N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.

31.

Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening.

Ren CL, Fink AK, Petren K, Borowitz DS, McColley SA, Sanders DB, Rosenfeld M, Marshall BC.

Pediatrics. 2015 Jun;135(6):e1386-92. doi: 10.1542/peds.2014-3698. Epub 2015 May 11.

32.

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial.

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group.

Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24.

PMID:
24973281
33.

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group.

Lancet Respir Med. 2014 Jul;2(7):539-47. doi: 10.1016/S2213-2600(14)70100-6. Epub 2014 May 15.

34.

Practice guidelines, clinical trials, and unexpected results in cystic fibrosis.

McColley SA.

Ann Am Thorac Soc. 2014 Mar;11(3):402-3. doi: 10.1513/AnnalsATS.201401-023ED. No abstract available.

PMID:
24673695
35.

Trichosporon mycotoxinivorans infection in patients with cystic fibrosis.

Shah AV, McColley SA, Weil D, Zheng X.

J Clin Microbiol. 2014 Jun;52(6):2242-4. doi: 10.1128/JCM.03309-13. Epub 2014 Mar 19.

36.

Sustained improvement in nutritional outcomes at two paediatric cystic fibrosis centres after quality improvement collaboratives.

Savant AP, Britton LJ, Petren K, McColley SA, Gutierrez HH.

BMJ Qual Saf. 2014 Apr;23 Suppl 1:i81-9. doi: 10.1136/bmjqs-2013-002314.

PMID:
24608554
37.
38.

Pancreatic enzyme replacement therapy dosing and nutritional outcomes in children with cystic fibrosis.

Haupt ME, Kwasny MJ, Schechter MS, McColley SA.

J Pediatr. 2014 May;164(5):1110-1115.e1. doi: 10.1016/j.jpeds.2014.01.022. Epub 2014 Feb 20.

PMID:
24560182
39.

Update in pediatric lung disease 2012.

McColley SA, Morty RE.

Am J Respir Crit Care Med. 2013 Aug 1;188(3):293-7. doi: 10.1164/rccm.201304-0617UP. Review. No abstract available.

PMID:
23905524
40.

A 15-year-old boy with dyspnea with exertion.

Listernick R, Trainor JL, McColley SA, Zimmerman D, Chadwick EG, Shulman ST, Curran ML, Alexander NS, Torchen L, Wadhwani N.

Pediatr Ann. 2013 Jun 1;42(6):227-9. doi: 10.3928/00904481-20130522-04. No abstract available.

PMID:
23718243
41.

Update in pediatric lung disease 2011.

McColley SA, Morty RE.

Am J Respir Crit Care Med. 2012 Jul 1;186(1):30-4. doi: 10.1164/rccm.201203-0568UP. Review. No abstract available.

PMID:
22753687
42.

Update in cystic fibrosis 2011.

Ratjen F, McColley SA.

Am J Respir Crit Care Med. 2012 May 1;185(9):933-6. doi: 10.1164/rccm.201202-0306UP. Review. No abstract available.

PMID:
22550209
43.

Risk factors for onset of persistent respiratory symptoms in children with cystic fibrosis.

McColley SA, Ren CL, Schechter MS, Regelmann WE, Pasta DJ, Konstan MW; Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2012 Oct;47(10):966-72. doi: 10.1002/ppul.22519. Epub 2012 Feb 22.

44.

Hispanic Infants with cystic fibrosis show low CFTR mutation detection rates in the Illinois newborn screening program.

Watts KD, Layne B, Harris A, McColley SA.

J Genet Couns. 2012 Oct;21(5):671-5. doi: 10.1007/s10897-012-9481-2. Epub 2012 Feb 4.

PMID:
22311127
45.

Lung function decline from adolescence to young adulthood in cystic fibrosis.

Vandenbranden SL, McMullen A, Schechter MS, Pasta DJ, Michaelis RL, Konstan MW, Wagener JS, Morgan WJ, McColley SA; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

Pediatr Pulmonol. 2012 Feb;47(2):135-43. doi: 10.1002/ppul.21526. Epub 2011 Aug 24.

46.

Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.

Trapnell BC, McColley SA, Kissner DG, Rolfe MW, Rosen JM, McKevitt M, Moorehead L, Montgomery AB, Geller DE; Phase 2 FTI Study Group.

Am J Respir Crit Care Med. 2012 Jan 15;185(2):171-8. doi: 10.1164/rccm.201105-0924OC. Epub 2011 Nov 17.

47.

Socioeconomic status and the likelihood of antibiotic treatment for signs and symptoms of pulmonary exacerbation in children with cystic fibrosis.

Schechter MS, McColley SA, Regelmann W, Millar SJ, Pasta DJ, Wagener JS, Konstan MW, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis.

J Pediatr. 2011 Nov;159(5):819-824.e1. doi: 10.1016/j.jpeds.2011.05.005. Epub 2011 Jun 25.

48.

Elevated vascular endothelial growth factor is correlated with elevated erythropoietin in stable, young cystic fibrosis patients.

Watts KD, McColley SA.

Pediatr Pulmonol. 2011 Jul;46(7):683-7. doi: 10.1002/ppul.21428. Epub 2011 Mar 1.

PMID:
21365780
49.

Clinical significance of microbial infection and adaptation in cystic fibrosis.

Hauser AR, Jain M, Bar-Meir M, McColley SA.

Clin Microbiol Rev. 2011 Jan;24(1):29-70. doi: 10.1128/CMR.00036-10. Review.

50.

Parental understanding of newborn screening for cystic fibrosis after a negative sweat-test.

Lang CW, McColley SA, Lester LA, Ross LF.

Pediatrics. 2011 Feb;127(2):276-83. doi: 10.1542/peds.2010-2284. Epub 2011 Jan 10.

PMID:
21220393

Supplemental Content

Loading ...
Support Center